$EPZM Catalyst.."So in 2014 we will be finishing our Phase 1 clinical studies initiating clinical studies in the pediatric populations in May, which we’ve achieved. Have ongoing Phase 1 dose escalation studies in 6438 that we expect to complete this year and present the data in the second half of this year. And then two proof-of-concept studies one in non-hodgkin lymphoma patients and one in INI1-deficient tumors like synovial sarcoma." -From latest quarterly transcript
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.